Nicorandil effects on platelet function, Hs-CRP, MMP-9 and myocardial antioxidation in patients with unstable angina

Peng,Ruijun; Yang,Xili; Liang,Xi

doi:10.3892/etm.2019.7918

Nicorandil effects on platelet function, Hs-CRP, MMP-9 and myocardial antioxidation in patients with unstable angina

Authors:
- Ruijun Peng
- Xili Yang
- Xi Liang
View Affiliations

Affiliations: Department of Cardiovascular Medicine, the First People's Hospital of FoShan (Affiliated FoShan Hospital of Sun Yat-sen University), Foshan, Guangdong 528000, P.R. China
Published online on: August 20, 2019 https://doi.org/10.3892/etm.2019.7918
Pages: 3095-3099
Copyright: © Peng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Nicorandil effects on platelet activation and myocardial antioxidant function in patients with unstable angina were studied. A total of 157 patients with unstable angina in the First People's Hospital of Foshan were selected and divided into experimental and control group. Patients in experimental group were treated with conventional drugs and nicorandil (15 min/day), t.i.d., for 21 days as one course of treatment, while those in control group were treated with conventional drugs. After treatment, serum indexes were detected and compared between the two groups of patients. Compared with that in control group, the platelet function of patients in the experimental group was significantly improved, and there was a statistically significant difference (P<0.05). Serum anti-oxidation factors in both groups were increased after treatment, and they were increased more significantly in experimental group (P<0.05). Serum inflammatory factors, high-sensitivity C-reactive protein and matrix metalloproteinase-9, also declined significantly in the experimental group. Nicorandil reduces inflammatory response and promotes stability of myocardial function in the treatment of unstable angina.

View Figures

View References

1	MacMahon S, Sharpe N, Gamble G, Hart H, Scott J, Simes J and White H; LIPID Trial Research Group, : Effects of lowering average of below-average cholesterol levels on the progression of carotid atherosclerosis: Results of the LIPID Atherosclerosis Substudy. Circulation. 97:1784–1790. 1998. View Article : Google Scholar : PubMed/NCBI
2	Hauser ER, Mooser V, Crossman DC, Haines JL, Jones CH, Winkelmann BR, Schmidt S, Scott WK, Roses AD, Pericak-Vance MA, et al Design of the Genetics of Early Onset Cardiovascular Disease study, : Design of the Genetics of Early Onset Cardiovascular Disease (GENECARD) study. Am Heart J. 145:602–613. 2003. View Article : Google Scholar : PubMed/NCBI
3	Vasilieva EJ, Shpector AV, Raskuragev AB, Lekochmacher SS and Bespalko IA: Platelet function and plasma lipid levels in patients with stable and unstable angina pectoris. Am J Cardiol. 68:959–961. 1991. View Article : Google Scholar : PubMed/NCBI
4	Ogawa H, Yasue H, Misumi I, Masuda T, Okumura K, Bannai S, Takanashi N and Tsukada Y: Plasma platelet-derived growth factor levels in coronary circulation in unstable angina pectoris. Am J Cardiol. 69:453–456. 1992. View Article : Google Scholar : PubMed/NCBI
5	Chakhtoura EY, Shamoon FE, Haft JI, Obiedzinski GR, Cohen AJ and Watson RM: Comparison of platelet activation in unstable and stable angina pectoris and correlation with coronary angiographic findings. Am J Cardiol. 86:835–839. 2000. View Article : Google Scholar : PubMed/NCBI
6	Fitzgerald DJ: Platelet activation in the pathogenesis of unstable angina: Importance in determining the response to plasminogen activators. Am J Cardiol. 68:51B–57B. 1991. View Article : Google Scholar : PubMed/NCBI
7	Fitzgerald DJ, Roy L, Catella F and FitzGerald GA: Platelet activation in unstable coronary disease. N Engl J Med. 315:983–989. 1986. View Article : Google Scholar : PubMed/NCBI
8	Frampton J, Buckley MM and Fitton A: Nicorandil. A review of its pharmacology and therapeutic efficacy in angina pectoris. Drugs. 44:625–655. 1992. View Article : Google Scholar : PubMed/NCBI
9	Kim JH, Jeong MH, Yun KH, Kim KH, Kang DK, Hong SN, Lim SY, Lee SH, Lee YS, Hong YJ, et al: Myocardial protective effects of nicorandil during percutaneous coronary intervention in patients with unstable angina. Circ J. 69:306–310. 2005. View Article : Google Scholar : PubMed/NCBI
10	Natarajan M: Unstable angina. Clin Evid. 8:225–235. 2002.
11	Xu FH and Wang JM: Clinical observation on acupuncture combined with medication for intractable angina pectoris Zhongguo Zhenjiu. 25:89–91. 2005.(In Chinese). PubMed/NCBI
12	Tada M: Unstable angina. Nippon Naika Gakkai Zasshi. 72:721–726. 1983.(In Japanese). View Article : Google Scholar : PubMed/NCBI
13	Ibuki C: Unstable angina. Nihon Rinsho. 2 (Suppl 5):234–239. 2007.(In Japanese).
14	Waters DD, Walling A, Roy D and Théroux P: Previous coronary artery bypass grafting as an adverse prognostic factor in unstable angina pectoris. Am J Cardiol. 58:465–469. 1986. View Article : Google Scholar : PubMed/NCBI
15	Faxon DP, Detre KM, McCabe CH, Fisher L, Holmes DR, Cowley MJ, Bourassa MG, Van Raden M and Ryan TJ: Role of percutaneous transluminal coronary angioplasty in the treatment of unstable angina. Report from the National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty and Coronary Artery Surgery Study Registries. Am J Cardiol. 53:131C–135C. 1984. View Article : Google Scholar : PubMed/NCBI
16	Lubsen J: Medical management of unstable angina. What have we learned from the randomized trials? Circulation. 82 (Suppl):II82–II87. 1990.PubMed/NCBI
17	Walker A, McMurray J, Stewart S, Berger W, McMahon AD, Dargie H, Fox K, Hillis S, Henderson NJ and Ford I: Economic evaluation of the impact of nicorandil in angina (IONA) trial. Heart. 92:619–624. 2006. View Article : Google Scholar : PubMed/NCBI
18	Kim SJ, Kim W, Woo JS, Ha SJ, Kang WY, Hwang SH, Kang DG, Lee SU, Cho SK, Im JS, et al: Effect of myocardial protection of intracoronary adenosine and nicorandil injection in patients undergoing non-urgent percutaneous coronary intervention: A randomized controlled trial. Int J Cardiol. 158:88–92. 2012. View Article : Google Scholar : PubMed/NCBI
19	Egred M: Nicorandil-associated ulcerations. Eur J Gastroenterol Hepatol. 19:395–398. 2007. View Article : Google Scholar : PubMed/NCBI
20	Gupta A and Morris G: Major aphthous ulcers induced by nicorandil. Age Ageing. 29:372–373. 2000. View Article : Google Scholar : PubMed/NCBI